Brazil clears Phytalix, the first ascaroside-based crop protection product registered anywhere
MAPA has registered the small-molecule biofungicide for soybeans and corn. It is Ascribe Bioscience's first commercial registration, and the first
Brazil's Ministry of Agriculture and Livestock (MAPA) has approved Phytalix, a small-molecule biofungicide from the US company Ascribe Bioscience, for use against major fungal and bacterial diseases affecting soybeans and corn. Ascribe announced the registration on 29 September 2026. It is the company's first commercial product registration, and Ascribe says it marks the first regulatory approval of an ascaroside-based biological crop protection product anywhere in the world.
The active ingredient is a synthesized ascaroside, a small molecule found in the soil microbiome, developed from discoveries at the Boyce Thompson Institute at Cornell University. Rather than acting directly on pathogens, it primes the plant's innate defenses. The company describes the product as shelf-stable, requiring neither refrigeration nor specialized equipment, and says it integrates into existing farming practices.
In Brazil the approval covers Asian soybean rust, target spot and Septoria in soybeans, and white spot (Phaeosphaeria) and Bipolaris in corn. Based on publicly available Brazilian registration data, Ascribe also describes Phytalix as the first biological product registered to control Bipolaris maydis. Chief executive Jay Farmer put the case for the product in terms of Brazilian growers needing sustainable disease control options that do not add complexity.
Brazil is the world's leading market for agricultural biologicals. Ascribe cites CropLife Brasil putting the country's bioinputs market at BRL 6.2 billion, approximately US$1.2 billion, in 2025, with biofungicides its fastest-growing segment. The company, based in Ithaca, New York and founded in 2017, has a registration pending in the United States. It also holds a development and supply agreement with Syngenta covering rice and other crops across 18 countries in Southeast Asia, and an R&D collaboration with Corteva to advance seed-treatment applications.
Why it matters for AgTech founders: the asset created here is a regulatory precedent more than a molecule. Ascaroside chemistry now has a label somewhere in the world, which means the next product in the class argues from a file that exists rather than from first principles, and first-in-class registrations are the expensive ones. Two sequencing decisions are worth copying. Ascribe registered in Brazil before its home market and still has the United States pending, choosing the first jurisdiction by market size and regulatory throughput rather than by where the lab sits. And it kept the registration while renting the reach, partnering rice in Southeast Asia to Syngenta and seed treatment to Corteva, so the owned asset is the active ingredient plus the label while distribution runs on someone else's balance sheet. The harder test is still ahead. Defense priming has a long record of products that performed in trials and underwhelmed in the field, and a label naming Asian soybean rust and Bipolaris maydis is a far more falsifiable claim than a general plant-health positioning. For founders in biologicals, the named-pathogen label is what a distributor can actually sell against, and the extra trial work it costs should be priced in from the start.
Brazil clears Phytalix, the first ascaroside-based crop protection product registered anywhere
MAPA has registered the small-molecule biofungicide for soybeans and corn. It is Ascribe Bioscience's first commercial registration, and the first for an ascaroside anywhere in the world.
Brazil's Ministry of Agriculture and Livestock (MAPA) has approved Phytalix, a small-molecule biofungicide from the US company Ascribe Bioscience, for use against major fungal and bacterial diseases affecting soybeans and corn. Ascribe announced the registration on 29 September 2026. It is the company's first commercial product registration, and Ascribe says it marks the first regulatory approval of an ascaroside-based biological crop protection product anywhere in the world.
The active ingredient is a synthesized ascaroside, a small molecule found in the soil microbiome, developed from discoveries at the Boyce Thompson Institute at Cornell University. Rather than acting directly on pathogens, it primes the plant's innate defenses. The company describes the product as shelf-stable, requiring neither refrigeration nor specialized equipment, and says it integrates into existing farming practices.
In Brazil the approval covers Asian soybean rust, target spot and Septoria in soybeans, and white spot (Phaeosphaeria) and Bipolaris in corn. Based on publicly available Brazilian registration data, Ascribe also describes Phytalix as the first biological product registered to control Bipolaris maydis. Chief executive Jay Farmer put the case for the product in terms of Brazilian growers needing sustainable disease control options that do not add complexity.
Brazil is the world's leading market for agricultural biologicals. Ascribe cites CropLife Brasil putting the country's bioinputs market at BRL 6.2 billion, approximately US$1.2 billion, in 2025, with biofungicides its fastest-growing segment. The company, based in Ithaca, New York and founded in 2017, has a registration pending in the United States. It also holds a development and supply agreement with Syngenta covering rice and other crops across 18 countries in Southeast Asia, and an R&D collaboration with Corteva to advance seed-treatment applications.
Why it matters for AgTech founders: the asset created here is a regulatory precedent more than a molecule. Ascaroside chemistry now has a label somewhere in the world, which means the next product in the class argues from a file that exists rather than from first principles, and first-in-class registrations are the expensive ones. Two sequencing decisions are worth copying. Ascribe registered in Brazil before its home market and still has the United States pending, choosing the first jurisdiction by market size and regulatory throughput rather than by where the lab sits. And it kept the registration while renting the reach, partnering rice in Southeast Asia to Syngenta and seed treatment to Corteva, so the owned asset is the active ingredient plus the label while distribution runs on someone else's balance sheet. The harder test is still ahead. Defense priming has a long record of products that performed in trials and underwhelmed in the field, and a label naming Asian soybean rust and Bipolaris maydis is a far more falsifiable claim than a general plant-health positioning. For founders in biologicals, the named-pathogen label is what a distributor can actually sell against, and the extra trial work it costs should be priced in from the start.
